Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Recruiting now · Phase 2

Conditions studied: Alcohol Use Disorder, Alcoholism

In brief

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Key facts

Study ID

NCT05995769

Run by

University of Calgary

People needed

128

Starts

2024-03-20

Expected to finish

2027-10-01

Last updated by the study team

2024-05-07

Who can join

Age: 22 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets DSM-5 AUD criteria of at least moderate severity
• Meets heavy drinking requirements (heavy drinking days, number of drinks) in past 30 days
• Desire to decrease alcohol consumption
• Limited lifetime hallucinogen use

You may not qualify if…

• Severe or moderate substance use disorder other than alcohol or nicotine in past 6 months
• Diagnosis of schizophrenia, bipolar disorders or first-degree relative with diagnosis
• Active suicidal ideation or serious attempt within past 3 years
• Currently pregnant, nursing, or trying to become pregnant
• Any notable abnormality on ECG, physical exam, or routine medical blood laboratory test

Where it is running

• University of Calgary — Calgary, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.